LIXTW · NOMAD Power Solutions, Inc.

Summary

Lixte Biotechnology Holdings, Inc. reported widening operating and net losses for FY 2025, driven by increased administrative expenses and a strategic pivot toward the Liora proton therapy acquisition. The company maintained steady cash usage in operations while navigating a significant transition in its clinical development strategy.

Key takeaways

• Operating loss widened 43.0% to -$5.1M, reflecting increased investment in administrative infrastructure and strategic corporate development activities.
• Net loss deepened 69.5% to -$6.1M, impacted by operating expenses and other costs associated with strategic transactions during the fiscal year.
• Diluted EPS improved 20.8% to -$1.26, indicating that the increased net loss was partially offset by share count dynamics.
• Cash used in operations remained relatively steady at -$3.1M, compared to -$3.2M in the prior year, demonstrating consistent operational cash management.
• The Company is actively preparing for the GEIS clinical trial in Spain, engaging vendors to manufacture new LB-100 inventory supplies.